Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

Luye Pharma’s Shandong Boan Biotechnology IPOs on Hong Kong Stock Exchange

Fineline Cube Dec 19, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary Shandong Boan Biotechnology Co., Ltd has officially...

Company Drug

Simcere Pharmaceutical Completes Enrollment for SIM0417 COVID-19 Drug Trial

Fineline Cube Dec 19, 2022

China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the completion of enrollment of 1,208 patients...

Company Drug

Neurophth’s NFS-02 Gene Therapy Gets FDA IND Approval for LHON Treatment

Fineline Cube Dec 19, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced obtaining Investigational New Drug (IND) approval...

Company Drug

TG ImmunoPharma Gains FDA Approval for Phase I Study of Anti-PVRIG Antibody

Fineline Cube Dec 19, 2022

China-based TG ImmunoPharma Co., Ltd has announced receiving the go-ahead from the US FDA to...

Company Deals Drug

Adagene Initiates International Study for ADG126 in Hepatocellular Carcinoma

Fineline Cube Dec 19, 2022

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Company Drug

Jiangsu Recbio’s Herpes Zoster Vaccine REC610 Gets Clinical Trial Approval in Philippines

Fineline Cube Dec 19, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced receiving clinical trial...

Company Deals

Endo International Licenses TLC’s Phase III Nanomedicine for OA Knee Pain

Fineline Cube Dec 19, 2022

Ireland-based Endo International plc (NASDAQ: ENDP) has announced a licensing deal between its subsidiary Endo...

Company Drug

GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor

Fineline Cube Dec 19, 2022

China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...

Company Medical Device

Blue Sail Medical’s Microcatheter Receives NMPA Marketing Approval

Fineline Cube Dec 19, 2022

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced obtaining marketing approval from the...

Company Deals

Meihua Medtech Secures Over RMB 100M in Series B Financing Led by Eight Roads and Sunland

Fineline Cube Dec 19, 2022

China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider,...

Company Deals

InnerMedical Secures RMB 300M in Series D Funding Led by Green Pine and Simiao

Fineline Cube Dec 19, 2022

InnerMedical Co., Ltd, a leading chronic disease diagnosis and treatment solutions provider based in Shenzhen,...

Company

Novartis China Establishes Health Development Fund in Boao Lecheng

Fineline Cube Dec 19, 2022

Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant...

Company Drug

Henlius’ Serplulimab Receives Orphan Drug Designation in Europe for SCLC

Fineline Cube Dec 16, 2022

Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the...

Company Deals

XingImaging and Mitro Biotech Partner for Contract Research Services in China

Fineline Cube Dec 16, 2022

US-based XingImaging LLC and China-based Mitro Biotech Co., Ltd have announced a partnership to provide...

Company Drug

Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303

Fineline Cube Dec 16, 2022

China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...

Company Policy / Regulatory

WuXi Biologics’ Shanghai Subsidiary Removed from US UVL

Fineline Cube Dec 16, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Policy / Regulatory

Liaoning Publishes Fourth Round of Volume-Based Procurement Winning Bids

Fineline Cube Dec 16, 2022

The Liaoning drug and medical consumables centralized procurement website has published the fourth round of...

Company Deals

Cryofocus Medtech Set for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 16, 2022

China-based Cryofocus Medtech (Shanghai) Co., Ltd, a minimally invasive interventional cryotherapy device maker, is set...

Company Medical Device

NMPA Approves SonoScape and Acoustic Life’s Intravascular Ultrasound Products

Fineline Cube Dec 16, 2022

The National Medical Products Administration (NMPA) has approved Chinese firms SonoScape Medical Corp’s intravascular ultrasound...

Company Drug

Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis

Fineline Cube Dec 15, 2022

German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA)...

Posts pagination

1 … 608 609 610 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.